<DOC>
	<DOC>NCT02173821</DOC>
	<brief_summary>This is a follow-up study of patients, treated with one daily dose of Zomacton or one daily dose of Genotropin in the previously completed FE 999905 CS07 trial, who had presence of anti-hGH antibodies at any post-dosing visit during the 12-month treatment period. No investigational medicinal product will be administered in connection with this follow-up study. Eligible patients will attend one visit in this follow-up study.</brief_summary>
	<brief_title>A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Previous participation in trial FE 999905 CS07 and presence of antihGH antibodies at any postdosing visit throughout the 12month treatment period Signed informed consent and obtained assent according to local rules and practice Information on medical history, concomitant medications, and growth hormone therapy since completion of trial FE 999905 CS07 There are no predefined exclusion criteria in this study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>